A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER plus ) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorMirza, M. R.
dc.contributor.authorBjorge, L.
dc.contributor.authorMarme, F.
dc.contributor.authorChristensen, R. DePont
dc.contributor.authorGil-Martin, M.
dc.contributor.authorAuranen, A.
dc.contributor.authorAtaseven, B.
dc.contributor.authorRubio, M. J.
dc.contributor.authorSalutari, V.
dc.contributor.authorLund, B.
dc.contributor.authorRunnebaum, I.
dc.contributor.authorRedondo, A.
dc.contributor.authorLindemann, K.
dc.contributor.authorTrillsch, F.
dc.contributor.authorBarretina Ginesta, M. P.
dc.contributor.authorRoed, H.
dc.contributor.authorLohndorf, J.
dc.contributor.authorNyvang, G-B.
dc.contributor.authorSehouli, J.
dc.contributor.authoraffiliation[Mirza, M. R.] Nord Soc Gynaecol Oncol NSGO, Dept Oncol, Copenhagen, Denmark
dc.contributor.authoraffiliation[Mirza, M. R.] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
dc.contributor.authoraffiliation[Bjorge, L.] Nord Soc Gynaecol Oncol NSGO CTU, Dept Gynaecol Oncol, Bergen, Denmark
dc.contributor.authoraffiliation[Bjorge, L.] Haukeland Hosp, Bergen, Denmark
dc.contributor.authoraffiliation[Bjorge, L.] Univ Bergen, Ctr Biomarkers CCBIO, Bergen, Denmark
dc.contributor.authoraffiliation[Marme, F.] UMM Univ Klinikum Mannheim, Fak Med, Dept Gynecol Oncol, Mannheim, Germany
dc.contributor.authoraffiliation[Christensen, R. DePont] Nord Soc Gynaecol Oncol NSGO CTU, Dept Biostat, Odense, Denmark
dc.contributor.authoraffiliation[Christensen, R. DePont] Univ Southern Denmark, Inst Publ Hlth, Odense, Denmark
dc.contributor.authoraffiliation[Gil-Martin, M.] GEICO, Oncol, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Gil-Martin, M.] Inst Catala Oncol IDIBELL, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Auranen, A.] NSGO CTU, Dept Obstet & Gynecol, Tampere, Finland
dc.contributor.authoraffiliation[Auranen, A.] Tampere Univ Hosp Tays, Tampere, Finland
dc.contributor.authoraffiliation[Ataseven, B.] NOGGO, Gynaecol, Essen, Germany
dc.contributor.authoraffiliation[Ataseven, B.] Kliniken Essen Mitte Evang Huyssens Stiftung, Essen, Germany
dc.contributor.authoraffiliation[Rubio, M. J.] GEICO, Gynecol, Cordoba, Spain
dc.contributor.authoraffiliation[Rubio, M. J.] Univ Hosp Reina Sofia, Cordoba, Spain
dc.contributor.authoraffiliation[Salutari, V.] MITO, Dept Gynecol Oncol, Rome, Italy
dc.contributor.authoraffiliation[Salutari, V.] Policlin Univ A Gemelli, Rome, Italy
dc.contributor.authoraffiliation[Lund, B.] Nord Soc Gynaecol Oncol NSGO CTU, Dept Oncol, Aalborg, Denmark
dc.contributor.authoraffiliation[Lund, B.] Aalborg Univ Hosp, Aalborg, Denmark
dc.contributor.authoraffiliation[Runnebaum, I.] NOGGO, Gynaecol, Munich, Germany
dc.contributor.authoraffiliation[Runnebaum, I.] Klin Frauenheilkunde & Fortpflanzungsmed, Munich, Germany
dc.contributor.authoraffiliation[Redondo, A.] GEICO, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Redondo, A.] Hosp Univ La Paz, Madrid, Spain
dc.contributor.authoraffiliation[Lindemann, K.] NSGO CTU, Dept Gynecol Canc, Oslo, Norway
dc.contributor.authoraffiliation[Lindemann, K.] Norwegian Radium Hosp, Oslo Univ Hosp, Oslo, Norway
dc.contributor.authoraffiliation[Trillsch, F.] NOGGO, Dept Gynecol & Obstet, Munich, Germany
dc.contributor.authoraffiliation[Trillsch, F.] Klinikum Univ Munchen, Munich, Germany
dc.contributor.authoraffiliation[Barretina Ginesta, M. P.] GEICO, Dept Med Oncol, Girona, Spain
dc.contributor.authoraffiliation[Barretina Ginesta, M. P.] Hosp Univ Josep Trueta, ICO Inst Catala Oncol Girona, Girona, Spain
dc.contributor.authoraffiliation[Roed, H.] NSGO CTU, Dept Oncol 3994, Copenhagen, Denmark
dc.contributor.authoraffiliation[Roed, H.] Rigshosp, Copenhagen, Denmark
dc.contributor.authoraffiliation[Lohndorf, J.] Rigshosp, NSGO CTU Nord Soc Gynaecol Oncol, NSGO, Copenhagen, Denmark
dc.contributor.authoraffiliation[Nyvang, G-B.] NSGO CTU, Dept Oncol, Odense, Denmark
dc.contributor.authoraffiliation[Nyvang, G-B.] Odense Univ Hosp, Odense, Denmark
dc.contributor.authoraffiliation[Sehouli, J.] NOGGO, Gynecol, Berlin, Germany
dc.contributor.authoraffiliation[Sehouli, J.] Univ Klin Charite, Campus Virchow Klinikum, Berlin, Germany
dc.contributor.funderPfizer
dc.date.accessioned2025-01-07T13:12:58Z
dc.date.available2025-01-07T13:12:58Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.2258
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420423403/pdf
dc.identifier.urihttps://hdl.handle.net/10668/25337
dc.identifier.wosID573469102656
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.page.numberS1160-S1160
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleA randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER plus ) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía